Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Louis Fehrenbacher

Showing results (1-10 of 90) with videos related to

Pageof 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2014
Reply to L. Cabel et alLouis Fehrenbacher, Angela Capra, Laurel Habel
Journal of Oncology Practice|October 24, 2013
Effect of medical oncologists' attitudes on accrual to clinical trials in a community settingCarol P Somkin, Lynn Ackerson, Gail Husson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2014
Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery systemLouis Fehrenbacher, Angela M Capra, Charles P Quesenberry, et al.
Breast Cancer Research and Treatment|December 2, 2005
Use of raloxifene among women with a history of breast cancerLaurel A Habel, Alice Pressman, Bruce Ettinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2002
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancerFairooz Kabbinavar, Herbert I Hurwitz, Louis Fehrenbacher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2005
Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancerHerbert I Hurwitz, Louis Fehrenbacher, John D Hainsworth, et al.
Investigational New Drugs|July 10, 2007
Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxelTomasz M Beer, Celestia S Higano, Mansoor Saleh, et al.
Journal of Surgical Oncology|August 25, 2005
Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumabFrank A Scappaticci, Louis Fehrenbacher, Thomas Cartwright, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2005
Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28Eleftherios P Mamounas, John Bryant, Barry Lembersky, et al.
Breast Cancer Research and Treatment|August 31, 2010
Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancerDawn L Hershman, Theresa Shao, Lawrence H Kushi, et al.
Pageof 9

Showing results (1-10 of 90) with videos related to

Sort By:
Pageof 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2014
Reply to L. Cabel et alLouis Fehrenbacher, Angela Capra, Laurel Habel
Journal of Oncology Practice|October 24, 2013
Effect of medical oncologists' attitudes on accrual to clinical trials in a community settingCarol P Somkin, Lynn Ackerson, Gail Husson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2014
Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery systemLouis Fehrenbacher, Angela M Capra, Charles P Quesenberry, et al.
Breast Cancer Research and Treatment|December 2, 2005
Use of raloxifene among women with a history of breast cancerLaurel A Habel, Alice Pressman, Bruce Ettinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2002
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancerFairooz Kabbinavar, Herbert I Hurwitz, Louis Fehrenbacher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2005
Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancerHerbert I Hurwitz, Louis Fehrenbacher, John D Hainsworth, et al.
Investigational New Drugs|July 10, 2007
Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxelTomasz M Beer, Celestia S Higano, Mansoor Saleh, et al.
Journal of Surgical Oncology|August 25, 2005
Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumabFrank A Scappaticci, Louis Fehrenbacher, Thomas Cartwright, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2005
Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28Eleftherios P Mamounas, John Bryant, Barry Lembersky, et al.
Breast Cancer Research and Treatment|August 31, 2010
Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancerDawn L Hershman, Theresa Shao, Lawrence H Kushi, et al.
Pageof 9